OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2015.3503 OL-0-0-3503 Articles MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma ZHANGJUFENG 1 2 3 WANGDAPING 2 3 XIONGJIANYI 2 3 CHENLEI 2 3 HUANGJIANGHONG 2 3 Department of Biological Sciences, School of Life Science, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China Department of Orthopaedics, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518039, P.R. China Shenzhen Key Laboratory for Tissue Engineering, Shenzhen, Guangdong 518039, P.R. China Correspondence to: Professor Daping Wang, Department of Orthopaedics, Shenzhen Second People's Hospital, 3002 Sun Gang West Road, Shenzhen, Guangdong 518039, P.R. China, E-mail: generesearch@163.com 10 2015 17 07 2015 10 4 2135 2141 27082014 15052015 Copyright: © Zhang et al. This is an open access article distributed under the terms of a Creative Commons Attribution License. 2015 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

A body of evidence has indicated that microRNAs (miRNAs) may have significant roles in cancer. Aberrant expression of miRNAs has frequently been observed in various human malignancies, including osteosarcoma (OS). However, the roles of miRNAs in OS remain poorly understood. In the present study, high-throughput deep sequencing was performed to screen for deregulated miRNAs in OS. Screening identified 310 miRNAs which were significantly overexpressed and 41 miRNAs which were significantly downregulated (>2-fold) in OS samples, compared with adjacent non-tumor bone tissues. Among these miRNAs, miR-33a-5p was notably downregulated. TaqMan reverse transcription-polymerase chain reaction analysis further verified that miR-33a-5p expression was significantly reduced in a large cohort of human OS samples. Enhancing miR-33a-5p expression via transfection with miR-33a-5p precursor significantly inhibited OS cell growth, suggesting potential antitumor properties of miR-33a-5p. The results of the present study provide novel insights into the miRNAs involved in OS, and suggest that miR-33a-5p may function as a tumor suppressor in OS. Therefore, miR-33a-5p may be able to serve as a diagnostic and therapeutic target for OS treatment.

 osteosarcoma microRNA-33a-5p tumor suppressor gene Introduction

Osteosarcoma (OS) is the most common primary bone malignancy, which mainly occurs in children and young adolescents (1–3). OS is a complex tumor, characterized by numerous chromosomal alterations and extensive gene mutations (4,5). Numerous molecular studies of OS have been undertaken in recent years, the results of which have provided insight into the molecular pathogenesis of OS (4–9). However, the fundamental molecular mechanisms underlying the occurrence and development of this sarcoma remain to be fully elucidated. Despite significant advances in the development of multimodality treatments comprising wide tumor excision with aggressive adjuvant chemotherapy, the prognosis of patients with recurrent or metastatic OS remains poor (10,11). Therefore, the identification of novel molecular biomarkers to facilitate the early diagnosis and therapy of OS is required, in order to improve the clinical outcome of patients with OS (12).

MicroRNAs (miRNAs) are small non-coding RNAs of ~22 nucleotides, which have emerged as a major class of regulatory genes in animals and plants (13,14). miRNAs are estimated to regulate >30% of the human genome, and are therefore involved in diverse functions, including development, cell differentiation, regulation of the cell cycle and apoptosis (15). A number of studies have demonstrated that miRNA alterations are involved in the development of human cancer (16,17). miRNA genes were frequently demonstrated to be located in cancer-associated genomic regions or fragile sites, suggesting that miRNAs in the genome may be extensively involved in cancer (18). In addition, miRNAs may function as oncogenes or tumor suppressors depending on the nature of their targets (19–21).

Overexpressed miRNAs in various types of cancer, including the miR-17-92 cluster, which comprises 7 miRNAs and is located in intron 3 of the C13orf25 gene at 13q31.3, have been reported to function as oncogenes and accelerate tumor development (22,23). Tumor-suppressive miRNAs, for example the let-7 family, are located in fragile regions of the human genome, and their loss is indicative of poor prognosis in various types of human cancer (24). Accumulating evidence suggests that miRNA expression profiling may be used in the classification of human cancers, indicating the potential of miRNAs as a novel diagnostic and prognostic tools for various types of cancer (25).

Several recent studies have identified a number of dysregulated miRNAs in OS (26–29). Maire et al (30) performed miRNA expression profiling of seven OS samples and identified several aberrantly expressed miRNAs. Lulla et al (29) identified 22 differentially expressed miRNAs in OS tumor samples, compared with normal osteoblasts. However, given the number of aberrant miRNAs identified thus far, it was suggested that there may be additional miRNAs involved in OS, which remain to be identified. Recent advances in high-throughput deep sequencing have markedly increased the speed of the search for cancer-associated miRNAs (31,32). High-throughput deep sequencing indicates the expression levels of each miRNA in the miRNome, and is thus one of the most effective and accurate approaches for evaluation of global miRNA expression levels (33,34). To the best of our knowledge, deep sequencing of the miRNome associated with OS has not previously been performed, and such comprehensive analysis may provide insight into the molecular mechanisms of OS.

The present study aimed to comprehend current literature by complete profiling of OS miRNA expression patterns, and further evaluating significantly differentially expressed miRNAs and their effects on human OS cells in vitro.

 Materials and methods <sec> <title>Patients and samples

The primary OS samples and matched noncancerous bone tissue samples used for the high-throughput deep sequencing experiments were obtained from two patients with OS undergoing surgical resection at Shenzhen Second People's Hospital (Shenzhen, China). Collected samples were flash frozen in liquid nitrogen following surgery. All patients were informed about the aims of the specimen collection and provided written informed consent. For the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) verification, 32 OS samples were obtained from an archive of formalin-fixed, paraffin-embedded (FFPE) diagnostic tissues in the Pathology Department at Shenzhen Second People's Hospital, collected between 1990 and 2013. All tumor samples were high-grade OS of stage IIA or IIB, according to the Enneking system (35). The mean age of the patients was 21 years (range, 18–36 years), and 59% were male. All diagnoses were confirmed by an experienced pathologist. Specimens from 36 normal muscles of patients who had undergone orthopedic surgery were collected and immediately stored in liquid nitrogen prior to use as the negative controls. The study was approved by the ethics committee of Shenzhen Second People's Hospital.

 Identification of differentially expressed miRNAs

High-throughput deep sequencing was performed using the Illumina Cluster Station and Genome Analyzer II (Illumina Inc., San Diego, CA, USA). Small RNA library construction, sequencing and bioinformatics analysis was conducted as previously described (36,37). The miRNA expression levels were compared between OS samples and paired normal bone tissues to detect the differentially expressed miRNAs. The expression levels of miRNAs in two samples were first normalized to obtain the expression of transcripts per million, and the fold-change and P-values were then calculated from the normalized expression level. In general, if the adjusted P-values were <0.01 based on the Benjamini and Hochberg multiple testing correction (38) and there was a ≥2-fold change (OS samples/paired normal bone tissues) in the normalized expression, the miRNA was considered to be significantly differentially expressed.

 Total RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of miRNAs

FFPE samples were cut into 10-µm sections. Total RNA was isolated from FFPE samples using the Qiagen RNeasy FFPE protocol (Qiagen, Inc., Valencia, CA, USA). For surgical resection specimens, total RNA was extracted using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions.

RT-qPCR analysis of mature miR-33a-5p was performed in triplicate using the TaqMan MicroRNA assay kit (Ambion) according to the manufacturer's instructions. The RT reaction mixture was comprised of 10 ng total RNA, 1 mM deoxynucleotide triphosphates, 50 U Multiscribe Reverse Transcriptase, 1.5 µl 10X RT buffer, 0.188 µl RNase inhibitor and 3 µl 5X TaqMan MicroRNA RT primer for each reaction (15 µl). The RT reaction was performed under the following conditions: 16°C for 30 min; 42°C for 30 min and 85°C for 5 min, prior to holding at 4°C. Following RT, the complementary DNA products of the RT reaction were diluted 15 times. PCR was conducted using 1.33 µl of the diluted product in 20 µl PCR reaction mixture, comprising 1 µl TaqMan MicroRNA Assay and 10 µl TaqMan Universal PCR Master mix. Subsequently, amplification was performed under the following conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Relative expression was calculated using the comparative C(T) method (39) and normalized to the expression of RNU6B (Ambion).

miRNAs identified by high-throughput deep sequencing were validated using the miScript PCR System (Qiagen, Inc., Gaithersburg, MD, USA) according to the manufacturer's instructions. The RT reaction mixtures with the miScript II RT kit (Qiagen) contained 1 µg total RNA, 4 µl 5X miScript HiSpec buffer, 2 µl 10X miScript nucleics mix and 2 µl miScript reverse transcriptase mix for each reaction (20 µl). RT was performed under the following conditions: 37°C for 60 min, followed by 95°C for 5 min. Subsequently, the cDNA products of the RT reaction were diluted 15 times. PCR was performed with 1.5 µl of the diluted products in 20 µl PCR reaction mixture containing 10 µl 2X QuantiTect SYBR Green PCR master mix, 2 µl 10X miScript universal primer, 2 µl 10X miScript primer assay. Amplification was performed under the following conditions: 95°C for 15 min, followed by 40 cycles at 94°C for 15 sec, 55°C for 30 sec and 70°C for 30 sec. All reactions were performed in triplicate. Relative expression was calculated using the comparative C(T) method and normalized to the expression of RNU6B.

 Cell culture

The human U2-OS and MG-63 OS cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). U2-OS and MG-63 cells were cultured in McCoy's 5A media (modified with tricine; (Gibco Life Technologies, Grand Island, NY, USA) and minimum essential medium supplemented with 10% fetal bovine serum (Gibco), respectively. Cells were incubated at 37°C in a 5% CO2 atmosphere.

 miR-33a-5p precursor transfection

The miR-33a-5p precursor and random sequence CY3-labeled miR-Scramble were synthesized by Ambion. U2-OS and MG-63 cells were counted and plated at a density of 4×105 cells/well in 6-well plates for overnight incubation prior to transfection with 100 nM miR-33a-5p precursor or miR-Scramble using Lipofectamine® 2000 (Invitrogen Life Technologies, CA, USA) according to the manufacturer's instructions. Transfection efficiency was estimated by CY3-labeled miR-Scramble using a fluorescence microscope (Axio Observer A1; Zeiss, Jena, Germany).

 Cell proliferation assays

The effect of miR-33a-5p on cell proliferation was measured by WST-1 assay. Cells were counted and plated at a density of 3×103 cells/well in 96-well plates in triplicates. Cell viability was determined at 24, 48 and 72 h post-transfection. Spectrophotometry (Beckman DU spectrophotometer, Beckman-Coulter, Brea, CA, USA) was performed at λ=450 nm and λ ref=630 nm following incubation with 10 µl WST-1 (Roche Diagnostics, New York, NY, USA) for 2 h. Cell proliferation was evaluated using a colony formation assay. Briefly, cells were seeded in six-well plates (0.5×103 cells/well) and cultured for two weeks. Colonies were fixed with methanol for 10 min and stained with 1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA) for 1 min. Visible colonies (defined as containing >50 cells) in 10 random fields were manually counted. Each cell group was measured in triplicate.

 Statistical analysis

miR-33a-5p expression in OS samples and normal bone or muscle tissues were compared using the Mann-Whitney U test. Correlation was evaluated using Pearson's Correlation Coefficient. A comparison of means among two or more groups was performed using one-way analysis of variance or Student's t-test. All numerical data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS software version 11 (SPSS, Inc., Chicago, IL, USA).

 Results <sec> <title>miRNAs differentially expressed in OS and normal bone tissues

To investigate the expression profiles of miRNAs in OS and adjacent normal bone tissues, high-throughput deep sequencing was used to compare their expression levels. High-throughput deep sequencing revealed a series of miRNAs with altered expression in OS tissues: 310 miRNAs were significantly overexpressed and 41 miRNAs were significantly downregulated (>2-fold; adjusted P<0.05), compared with those of normal tissues (Fig. 1A). Among these differentially expressed miRNAs, a total of 47 miRNAs with >32-fold elevated expression levels and 17 miRNAs with expression levels reduced >4-fold were identified (Table I).

To further validate these differentially expressed miRNAs, eight miRNAs identified by high-throughput deep sequencing were re-examined by RT-qPCR. The eight miRNAs selected included the most upregulated miRNAs (miR-512-3p, miR-377-5p, miR-433-3p and miR-1323) and most downregulated miRNAs (miR-33a-5p, miR-551b-3p, miR-3613-5p and miR-144-3p) in OS. As illustrated in Fig. 1B, the Illumina deep sequencing data correlated with the RT-qPCR results (r=0.805; P<0.001), indicating the reliability of sequencing-based expression analysis.

 miR-33a-5p expression is decreased in paraffin-embedded OS samples

Subsequently, miR-33a-5p was further analyzed, as this was the most downregulated miRNA identified in the OS samples. To verify the expression levels of miR-33a in OS, miR-33a-5p expression levels were determined in 32 paraffin-embedded human OS samples and 36 normal muscle tissues by TaqMan RT-qPCR. As shown in Fig. 2A, miR-33a-5p expression was significantly downregulated in paraffin-embedded OS tissues, compared with that of normal muscle tissue (P=0.0238). These results suggested that miR-33a-5p may have a role in the pathogenesis of OS.

 miR-33a-5p inhibits OS cell proliferation

To investigate the functional role of miR-33a-5p in OS, human U2-OS and MG-63 OS cell lines were transfected with 100 nM chemically synthesized miR-33a-5p precursor, which mimics endogenous mature miR-33a-5p function. Cells transfected with 100 nM miR-Scramble (scrambled oligonucleotides) were used as the control. Transfection efficiency of miRNA in these two cell lines was estimated by CY3-labeled miR-Scramble (>80%; data not show). Additionally, 24 h post transfection, miR-33a-5p expression levels were evaluated by RT-qPCR. The results demonstrated that miR-33a-5p mimic enhanced miR-33a-5p expression by ~152-fold (P<0.001) in U2-OS cells and ~341-fold in MG-63 cells (P<0.001), compared with the scramble-transfected group (Fig. 2B). These results indicated that the miR-33a-5p precursor was able to effectively increase miR-33a-5p expression in U2-OS and MG-63 cells.

Following 48, 72 and 96 h of incubation, U2-OS and MG-63 cells overexpressing miR-33a-5p exhibited decreased cell proliferation, as compared with miR-Scramble-transfected cells, respectively (P<0.05; Fig. 3A). Consistent with these results, in the WST-1 assay, cells transfected with miR-33a-5p demonstrated formation of significantly fewer colonies than those of cells transfected with the miR-Scramble (P<0.001; Fig. 3B).

 Discussion

In the present study, miRNAs that were up- or downregulated in OS, as compared with matched noncancerous bone tissues, were detected through high-throughput deep sequencing. The results demonstrated that the expression levels of 310 miRNAs were increased and 41 miRNAs were decreased in the OS tissues. Among these, miR-512-3p, miR-377-5p, miR-433-3p and miR-1323 were the greatest upregulated miRNAs, whereas miR-33a-5p, miR-551b-3p, miR-3613-5p and miR-144-3p were the most decreased miRNAs in OS. These miRNAs were re-examined by RT-qPCR analysis and the results correlated with those of the sequencing analysis. Specifically, miR-33a-5p was decreased most in OS, which suggested that miR-33a-5p may have a role in the pathogenesis of OS.

To the best of our knowledge, the role of miR-33a-5p in OS has not previously been reported. miR-33a-5p has recently emerged as a key regulator of metabolism, and was shown to regulate cholesterol and lipid metabolism (40,41). miR-33a is downregulated in lung cancer cells and functions as a potent tumor suppressor, which decreases osteolytic bone metastasis via suppression of parathyroid hormone-related protein (42). miR-33a also functions as a tumor suppressor miRNA through its capacity to downregulate the expression of oncogenic kinase Pim-1 in K562 lymphoma and colon carcinoma (43,44). miR-33 family members have been associated with modulation of the expression of various genes involved in cell cycle regulation and proliferation (45,46). miR-33 decreases cellular proliferation and cell cycle progression via inhibition of cyclin-dependent kinase 6 and cyclin D1 (45,46). In the present study, miR-33a-5p was demonstrated to be downregulated in OS, while overexpression of miR-33a-5p by transfection, significantly attenuated OS cell growth in vitro.

The aberrant expression of miRNAs may occur via a number of mechanisms, for example by deletion in fragile regions of the genome containing cancer-suppressing miRNAs, as a result of inherent or spontaneous mutations in miRNA genes or following methylation of miRNA promoters (47–50). However, the mechanism by which miR-33a-5p is downregulated in OS remains to be elucidated.

In conclusion, the results of the present study demonstrated that multiple miRNAs are aberrantly expressed in human OS. Among these miRNAs, miR-33a-5p is significantly downregulated in the majority of OS tissues. miR-33a-5p demonstrated tumor suppressive abilities in vitro by inhibiting OS cell proliferation, which suggested that miR-33a-5p may have a tumor suppressor function in human OS. These results provide support for the rescue of miR-33a-5p expression via gene therapy, and demonstrated the potential use of miR-33a-5p as diagnostic marker or therapeutic tool for the treatment of human OS.

 Acknowledgements

The authors would like to thank their colleagues for their insight and technical support. The present study was supported by the National Natural Scientific Foundation of China (no. 81171447), the China Postdoctoral Science Foundation (no. 2013M531896) and the Shenzhen Science and Technology Foundation (nos. GJHZ20130412153906739 and ZDSY20120614154551201).

 References SweetnamROsteosarcomaBr J Hosp Med281161211982 DamronTAWardWGStewartAOsteosarcoma, chondrosarcoma and Ewing's sarcoma: National Cancer Data Base ReportClin Orthop Relat Res4594047200710.1097/BLO.0b013e318059b8c917414166 DorfmanHDCzerniakBBone cancersCancer75(1 Suppl)S203S210199510.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V TarkkanenMKarhuRKallioniemiAElomaaIKiviojaAHNevalainenJBöhlingTKaraharjuEHyytinenEKnuutilaSGains and losses of DNA sequences in osteosarcomas by comparative genomic hybridizationCancer Res551334133819957882332 AlRomaihKBayaniJVorobyovaJKaraskovaJParkPCZielenskaMSquireJAChromosomal instability in osteosarcoma and its association with centrosome abnormalitiesCancer Genet Cytogenet1449199200310.1016/S0165-4608(02)00929-912850370 RaglandBDBellWCLopezRRSiegalGPCytogenetics and molecular biology of osteosarcomaLab Invest82365373200210.1038/labinvest.378043111950895 HeJPHaoYWangXLYangXJShaoJFGuoFJFengJXReview of the molecular pathogenesis of osteosarcomaAsian Pac J Cancer Prev1559675976201410.7314/APJCP.2014.15.15.596725124559 BroadheadMLClarkJCMyersDEDassCRChoongPFThe molecular pathogenesis of osteosarcoma: A reviewSarcoma2011959248201110.1155/2011/95924821559216 KansaraMThomasDMMolecular pathogenesis of osteosarcomaDNA Cell Biol26118200710.1089/dna.2006.050517263592 TaboneMDKalifaCRodaryCRaquinMValteauCouanetDLemerleJOsteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapyJ Clin Oncol122614262019947989936 KempfBielackBBielackSSJurgensHBranscheidDBerdelWEExnerGUGöbelUHelmkeKJundtGKabischSFOsteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)J Clin Oncol23559568200510.1200/JCO.2005.04.06315659502 DavisAMBellRSGoodwinPJPrognostic factors in osteosarcoma: A critical reviewJ Clin Oncol1242343119948113851 ArteagaVazquezMCaballeroPerezJVielle-CalzadaJPA family of microRNAs present in plants and animalsPlant Cell1833553369200610.1105/tpc.106.04442017189346 ZhangBWangQPanXMicroRNAs and their regulatory roles in animals and plantsJ Cell Physiol210279289200710.1002/jcp.2086917096367 HwangHWMendellJTMicroRNAs in cell proliferation, cell death and tumorigenesisBr J Cancer96(Suppl)R40R44200717393584 ZhangLHuangJYangNGreshockJMegrawMSGiannakakisALiangSNaylorTLBarchettiAWardMRmicroRNAs exhibit high frequency genomic alterations in human cancerProc Natl Acad Sci USA10391369141200610.1073/pnas.050888910316754881 CalinGACroceCMMicroRNA signatures in human cancersNat Rev Cancer6857866200610.1038/nrc199717060945 CalinGASevignaniCDumitruCDHyslopTNochEYendamuriSShimizuMRattanSBullrichFNegriniMCroceCMHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancersProc Natl Acad Sci USA10129993004200410.1073/pnas.030732310114973191 VoorhoevePMMicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?Biochim Biophys Acta18057286201019747962 ChenCZMicroRNAs as oncogenes and tumor suppressorsN Engl J Med35317681771200510.1056/NEJMp05819016251533 ZhangBPanXCobbGPAndersonTAmicroRNAs as oncogenes and tumor suppressorsDev Biol302112200710.1016/j.ydbio.2006.08.02816989803 HayashitaYOsadaHTatematsuYYamadaHYanagisawaKTomidaSYatabeYKawaharaKSekidoYTakahashiTA polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferationCancer Res6596289632200510.1158/0008-5472.CAN-05-235216266980 DiosdadoBvan de WielMATerhaarSive Droste JSMongeraSPostmaCMeijerinkWJCarvalhoBMeijerGAMiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progressionBr J Cancer101707714200910.1038/sj.bjc.660503719672269 LeeYSDuttaAThe tumor suppressor microRNA let-7 represses the HMGA2 oncogeneGenes Dev2110251030200710.1101/gad.154040717437991 LuJGetzGMiskaEAAlvarezSaavedraELambJPeckDSweetCorderoAEbertBLMakRHFerrandoAAMicroRNA expression profiles classify human cancersNature435834838200510.1038/nature0370215944708 LiangWGaoBFuPXuSQianYFuQThe miRNAs in the pathgenesis of osteosarcomaFront Biosci (Landmark Ed)18788794201310.2741/414223276964 KobayashiEHornicekFJDuanZMicroRNA involvement in osteosarcomaSarcoma2012359739201210.1155/2012/35973922550419 JonesKBSalahZDel MareSGalassoMGaudioENuovoGJLovatFLeBlancKPalatiniJRandallRLmiRNA signatures associate with pathogenesis and progression of osteosarcomaCancer Res7218651877201210.1158/0008-5472.CAN-11-266322350417 LullaRRCostaFFBischofJMChouPMde F BonaldoMVaninEFSoaresMBIdentification of differentially expressed microRNAs in osteosarcomaSarcoma2011732690201110.1155/2011/73269021789031 MaireGMartinJWYoshimotoMChiltonMacNeillSZielenskaMSquireJAAnalysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcomaCancer Genet204138146201110.1016/j.cancergen.2010.12.01221504713 LeidingerPKellerABorriesAReichrathJRassKJagerSULenhofHPMeeseEHigh-throughput miRNA profiling of human melanoma blood samplesBMC Cancer10262201010.1186/1471-2407-10-26220529253 GillisAJStoopHJHersmusROosterhuisJWSunYChenCGuentherSSherlockJVeltmanIBaetenJHigh-throughput microRNAome analysis in human germ cell tumoursJ Pathol213319328200710.1002/path.223017893849 SchotteDAkbariMoqadam FLange-TurenhoutEAChenCvan IjckenWFPietersRden BoerMLDiscovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemiaLeukemia2513891399201110.1038/leu.2011.10521606961 LeptidisSEl AzzouziHLokSIde WegerROlieslagersSKistersNSilvaGJHeymansSCuppenEBerezikovEA deep sequencing approach to uncover the miRNOME in the human heartPLoS One8e57800201310.1371/journal.pone.005780023460909 EnnekingWFSpanierSSGoodmanMAA system for the surgical staging of musculoskeletal sarcomaClin Orthop Relat Res15310612019807449206 ZhangJLuoXLiHDengLWangYGenome-wide uncovering of STAT3-mediated miRNA expression profiles in colorectal cancer cell linesBiomed Res Int2014187105201425126546 ZhangJWangYZhenPLuoXZhangCZhouLLuYYangYZhangWWanJGenome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell linesPLoS One8e54111201310.1371/journal.pone.005411123359607 YekutieliDBenjaminiYResampling-based false discovery rate controlling multiple test procedures for correlated test statisticsJ Stat Plan Inference82171196199910.1016/S0378-3758(99)00041-5 SchmittgenTDLivakKJAnalyzing real-time PCR data by the comparative C(T) methodNat Protoc311011108200810.1038/nprot.2008.7318546601 GoedekeLFernández-HernandoCmicroRNAs: A connection between cholesterol metabolism and neurodegenerationNeurobiol Dis724853201410.1016/j.nbd.2014.05.03424907491 GoedekeLValesLaraFMFenstermakerMCireraSalinasDChamorroJorganesARamírezCMMattisonJAde CaboRSuárezYFernández-HernandoCA regulatory role for microRNA 33* in controlling lipid metabolism gene expressionMol Cell Biol3323392352201310.1128/MCB.01714-1223547260 KuoPLLiaoSHHungJYHuangMSHsuYLMicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related proteinBiochim Biophys Acta183037563766201310.1016/j.bbagen.2013.02.02223458685 ThomasMLangeGrunwellerKWeirauchUWeirauchUGutschDAignerAGrünwellerAHartmannRKThe proto-oncogene Pim-1 is a target of miR-33aOncogene31918928201210.1038/onc.2011.27821743487 IbrahimAFWeirauchUThomasMGrünwellerAHartmannRKAignerAMicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinomaCancer Res7152145224201110.1158/0008-5472.CAN-10-464521690566 IwakiriYA role of miR-33 for cell cycle progression and cell proliferationCell Cycle1110571058201210.4161/cc.11.6.1974422395363 CireraSalinasDPautaMAllenRMSalernoAGRamírezCMChamorroJorganesAWanschelACLasuncionMAMoralesRuizMSuarezYMir-33 regulates cell proliferation and cell cycle progressionCell Cycle11922933201210.4161/cc.11.5.1942122333591 CroceCMCauses and consequences of microRNA dysregulation in cancerNat Rev Genet10704714200910.1038/nrg263419763153 DattaJKutayHNasserMWNuovoGJWangBMajumderSLiuCGVoliniaSCroceCMSchmittgenTDMethylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesisCancer Res6850495058200810.1158/0008-5472.CAN-07-665518593903 WongKYYuLChimCSDNA methylation of tumor suppressor miRNA genes: A lesson from the miR-34 familyEpigenomics38392201110.2217/epi.10.7422126155 DelaCruz FMatushanskyIMicroRNAs in chromosomal translocation-associated solid tumors: Learning from sarcomasDiscov Med12307317201122031668

Evaluation of miRNA expression levels by deep sequencing and validation with RT-qPCR. (A) Scatter plot indicating the expression levels of known miRNAs in osteosarcoma and adjacent normal bone tissues. Blue, miRNAs equally expressed in osteosarcoma and normal bone tissue; red, miRNAs upregulated in osteosarcoma compared with those of normal bone tissue (adjusted P<0.05); green, miRNAs downregulated in osteosarcoma compared with those of normal bone tissue (adjusted P<0.05). (B) Validation of eight selected up- and downregulated miRNAs indicated that the results from deep sequencing correlated with the RT-qPCR results. miRNA, microRNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

miR-33a-5p expression is decreased in OS cells and tissues. (A) Relative expression of miR-33a-5p was evaluated by TaqMan (RT-qPCR). Human normal muscle RNAs were used as controls. miR-33a-5p expression was downregulated in OS tissues. (B) Confirmation of overexpression of miR-33a-5p in transfected cell lines by real-time PCR. OS cell lines U-2OS and MG-63 were transfected with miR-33a-5p precursor and miR-Scramble control, and the relative expression of miR-33a-5p was assessed by RT-qPCR. Values are presented as the mean ± standard deviation. miR, microRNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; OS, osteosarcoma.

Osteosarcoma cancer cell growth is suppressed by miR-33a-5p precursor overexpression. (A) WST-1 assay indicated that MG-63 and U2-OS cells transfected with miR-33a-5p precusor grew more slowly than cells transfected with miR-Scramble. (B) Colony formation assay of miR-33a-5p precusor and miR-Scramble-transfected MG-63 and U2-OS cells indicated that miR-33a-5p supressed colony formation. All data are presented as the mean ± standard deviation. *P<0.05; ***P<0.001 vs. miR-Scramble-transfected cells. miR, microRNA; NC, normal control.

Significantly differentially expressed known miRNAs in osteosarcoma.

miRNA ID Log2, fold-changea Adjusted P-value
Upregulated
  hsa-miR-512-3p 9.39 2.80×10−62
  hsa-miR-377-5p 8.90 1.95×10−9
  hsa-miR-433-3p 8.60 1.54×10−5
  hsa-miR-1323 8.45 4.72×10−5
  hsa-miR-337-3p 8.11 5.30×10−22
  hsa-miR-485-3p 8.07 8.00×10−56
  hsa-miR-6503-5p 8.07 8.08×10−7
  hsa-miR-656-3p 7.99 <0
  hsa-miR-411-3p 7.94 6.82×10−8
  hsa-miR-494-3p 7.85 1.98×10−4
  hsa-miR-4709-5p 7.81 7.79×10−4
  hsa-miR-508-3p 7.76 1.23×10−6
  hsa-miR-187-3p 7.54 6.42×10−12
  hsa-miR-370-5p 7.54 4.12×10−9
  hsa-miR-105-3p 7.42 1.08×10−105
  hsa-miR-873-3p 7.37 3.22×10−4
  hsa-miR-1185-5p 7.07 1.36×10−51
  hsa-miR-541-3p 7.07 7.67×10−6
  hsa-miR-885-5p 7.07 3.50×10−16
  hsa-miR-329-5p 6.99 7.26×10−4
  hsa-miR-337-5p 6.99 1.84×10−3
  hsa-miR-219a-1-3p 6.90 2.34×10−13
  hsa-miR-329-3p 6.90 <0
  hsa-miR-134-3p 6.81 <0
  hsa-miR-134-5p 6.80 1.83×10−22
  hsa-miR-654-5p 6.77 <0
  hsa-miR-758-3p 6.77 1.44×10−5
  hsa-miR-487b-3p 6.72 2.48×10−6
  hsa-miR-20b-3p 6.71 3.18×10−292
  hsa-miR-380-3p 6.71 3.27×10−5
  hsa-miR-654-3p 6.42 4.30×10−31
  hsa-miR-432-5p 6.35 1.67×10−16
  hsa-miR-105-5p 6.25 3.64×10−22
  hsa-miR-409-3p 6.21 2.26×10−3
  hsa-miR-1269b 5.97 9.01×10−4
  hsa-miR-493-3p 5.93 5.29×10−97
  hsa-miR-431-3p 5.73 <0
  hsa-miR-127-3p 5.57 3.27×10−11
  hsa-miR-409-5p 5.56 5.01×10−3
  hsa-miR-370-3p 5.54 5.75×10−7
  hsa-miR-767-5p 5.54 2.20×10−7
  hsa-miR-410-3p 5.54 9.27×10−3
  hsa-miR-493-5p 5.51 <0
  hsa-miR-487a-3p 5.50 1.24×10−8
  hsa-miR-520a-3p 5.41 4.47×10−10
  hsa-miR-381-3p 5.24 4.87×10−14
  hsa-miR-149-5p 5.22 1.42×10−3
Downregulated
  hsa-miR-33a-5p −7.46 <0
  hsa-miR-551b-3p −6.98 6.63×10−5
  hsa-miR-3613-5p −5.17 1.53×10−3
  hsa-miR-144-3p −4.47 <0
  hsa-miR-190a-5p −3.28 6.73×10−83
  hsa-miR-335-5p −2.90 1.59×10−9
  hsa-miR-144-5p −2.75 9.27×10−13
  hsa-miR-224-3p −2.71 1.72×10−140
  hsa-miR-193a-3p −2.46 1.63×10−55
  hsa-miR-19a-3p −2.46 4.56×10−6
  hsa-miR-33b-5p −2.26 <0
  hsa-miR-452-3p −2.17 9.84×10−289
  hsa-miR-29c-3p −2.12 1.43×10−18
  hsa-miR-101-3p −2.11 <0
  hsa-miR-2467-5p −2.10 5.55×10−10
  hsa-miR-378a-5p −2.08 1.13×10−5
  hsa-miR-145-5p −2.04 1.22×10−7

fold change = (osteosarcoma/normal bone tissue). miR/miRNA, microRNA; ID, identification; hsa, Homo sapiens.